I feel a lot better today after the dr been interview last night and the 2nd PR further explaining the situation. It is clear leronlimab works is a broad spectrum of patients. This is huge info, this drug is not specific to a narrow symptom or patient condition, it works. The problem is that we had too small of a trial and the wrong PE. Many here have raised the concern about the arbitrary 28 day mortality and its problems. Few here realized (including myself) that when you have a relatively small trial, the range of patient recruitment leads to in related comparisons and making it difficult to present a conclusive apples to apples assessment. If this was a 1000+ patient trial, we would not have the problem with too many over 65 on treatment and too few in placebo. We essentially have a phase 2 trial with a ton of solid data. Any way the data was sliced, leronlimab works. The fact that we might need to add 140 patients is extremely encouraging. It says the FDA gets it, they just need the trial to have a end conclusion that allows them to approve. They know the drug works. We also don’t know if this added protocol is even needed, the higher ups are looking at this and they are the ones to bend the rules. Nader is just following the rules.
If we had a larger trial that could lead to approval, we would be still enrolling today. With this data out, I think it will be easy to enroll. It will take a couple months, but we know it will work, there is no guessing.
Also, compare this situation to all other treatment options. Those trials had to be mined to get some showing of effectiveness. With CD12, no matter how you look at it the drug works, the trial design is the problem that prevents the P value. The extension is purely to fix the trial problem, not to twist the data to make a drug that does not work look like it does.
Let’s also keep in mind, the data is out, anyone from the medical community and the BP world can see this drug just proved it is not just an HIV drug. BP now has the luxury of approaching cytodyn knowing they both know what leronlimab can do. The very near term data from Nash and the cancer basket trial will really put the spotlight on this. The world does not need to understand, the industry now does.
In today's era, technology has revolutionized sectors, including the mortgage referral program industry. By harnessing technology's capabilities, mortgage referral programs have become more efficient, streamlined, and accessible. This article will delve into how technology plays a role in these programs and its advantages for both lenders and customers.
Streamlining Referral Procedures:
One of the benefits of incorporating technology into mortgage referral programs is streamlining ... Continue Reading
Category: BusinessTotal Views: 120 By : EditorUpdated: 05-28-2024
Email is undoubtedly the main channel of communication for businesses, nevertheless, many encounter the problem of finding their vital messages in junk folders. Such can create a barrier to communication and to the effective performance of business representatives. Also, it can lead to reputation damage. Learning why emails get into spam as well as what to do to stop it is a vital thing to learn because lots of emails never get to their destination due to spam. Here are seven common reasons your... Continue Reading
Category: BusinessTotal Views: 104 By : EditorUpdated: 05-28-2024
The outsourcing approach can significantly transform your business’s operational dynamics. It is an effective strategy as your business advances through different stages. The global market mainly focuses on effectiveness, productivity, and expansion. For this reason, there is a growing number of small enterprises that outsource functions to enhance the quality of their connections with their customers.
Although outsourcing can boost your business, you should carefully consider the short... Continue Reading
Category: StocksTotal Views: 135 By : EditorUpdated: 05-28-2024
Introduction
Renewable energy is slowly becoming a new norm across the world mainly due to a rise in consciousness regarding climate change and policies as well as technological progress. In 2024 and the subsequent years, the investment in the green energy sector is expected to present promising investment prospects. In the article below we aim at delivering the potential investors with the panoramic view of the green energy sector in terms of the current state, trends, key players, and inves... Continue Reading
Category: StocksTotal Views: 121 By : EditorUpdated: 05-28-2024
Canopy Growth Corp. (NASDAQ:CGC) Executive Summary
Canopy Growth Corporation (NASDAQ:CGC) is a company that has managed to find a place for itself in the ever-growing cannabis market. It stands out due to the variety of its goods and services as well as strategic partnerships that it has established. The company however had its own share of difficulties such as being regulated strictly and experiencing huge changes in demand. This document contains detailed information about Canopy’s fi... Continue Reading
Category: BusinessTotal Views: 102 By : EditorUpdated: 05-28-2024
Introduction: Key Trends in 2024
As we make our way through 2024, the landscape that small businesses need to navigate changes just as quickly. Small businesses continue to evolve and adapt in response to an ever-changing marketplace, influenced by technology advances and shifts in consumer behavior. Below we discuss and go over 10 important trends for small businesses in 2024.
1. Digital Transformation
The Evolution of AI Tools and Integration
Artificial Intelligence (AI) is no long... Continue Reading
Category: StocksTotal Views: 163 By : EditorUpdated: 05-28-2024
Mullen Automotive, Inc. (NASDAQ: MULN) Executive Summary
Mullen Automotive, Inc. (NASDAQ: MULN) is an innovative Nanotech Energy Company focused on the manufacturing and distribution of electric vehicles along with developing and pioneering solid-state polymer battery technology. Although it is operating with a fresh take, as well as having recently formed key Strategic Alignments, Mullen Automotive has an established process of significant unpredictability and liability in its financial outp... Continue Reading
Category: Real EstateTotal Views: 228 By : EditorUpdated: 05-27-2024
Introduction: Understanding Rising Interest Rates in 2024
The CRE market is an operative and volatile industry that depends on several factors that reflect and determine its performance: one of the most significant ones is interest rates. Finally, as from 2024 there is a relatively high risk of raising interest rates that has an impact on investors, developers and other participants of the CRE market. This paper focuses on the scenarios and impact that the rising interest rate trends pose on ... Continue Reading
Category: MarketsTotal Views: 312 By : EditorUpdated: 05-27-2024
Introduction: Sector Performance in May 2024
As we turn the page on May 2024, investors are eager to hear which sectors are on the up or down, and which might still be troubled by wind in their face of a new month come. Various data, persistent inflation as well as the Federal Reserve's unpredictable signals were major factors in how May unfolded for various sectors. The S&P 500 fell by 4.16% in terms of returns – clearly investors are faced with an ever-changing environment. Th... Continue Reading
Introduction: Setting the Stage for Financial Success
As we quickly move into the second half of 2024, it is the perfect time to come up with new plans to achieve your financial goals. It is widely acknowledged that personal finance tends to involve the allocation of money over time toward the purchase of financial goods and services that meet an individual's needs and help him or her achieve personal goals and objectives. Here are the major financial goals that you should consider for th... Continue Reading